SCOHIA PHARMA and Kuria Therapeutics Announce Issuance of Key Patent Covering Novel Nrf2 Activator

SCOHIA PHARMA, Inc. and Kuria Therapeutics announced that the US Patent Office has issued a composition-of-matter patent covering SCO-116, a novel Nrf2 activator being developed by Kuria for prevention and treatment of eye and skin diseases.